Announced Thu, 2 Jul · 13:51 IST
Ajanta Pharma Paithan facility gets VAI from US FDA
Regulatory & Legal View source PDF
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹3345.10
prior close
₹3305.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+0.5+0.9+1.1-0.2+0.9-0.9-1.8-1.2+2.4+2.6———
Up moveDown movePending
AI summary
Ajanta Pharma received the Establishment Inspection Report from the US FDA for its Paithan, Maharashtra manufacturing facility. The inspection has been classified as Voluntary Action Indicated (VAI), meaning the facility is in acceptable condition with no mandatory corrective action required. The cGMP inspection was conducted from 13 April to 21 April 2026.
Likely market impact
Positive outcome — VAI means no FDA action needed, supports continued US exports from Paithan and removes near-term compliance uncertainty.